Introduction
============

*MORT* was originally found as a transcript silenced during *in vitro* immortalization of human mammary epithelial cells ^[@ref-1]^. Like a significant majority of lncRNAs, *MORT*'s molecular function remains enigmatic. The *MORT* gene is specific to higher primates, is expressed in all normal human cell types, and *MORT* RNA is located predominantly in the cytoplasm ^[@ref-1]^. Analysis of *MORT* expression and the DNA methylation state of its promoter in 17 cancer types from The Cancer Genome Atlas (TCGA) ^[@ref-2]^, which represent the 10 most frequent cancers in males and females, showed *MORT* is epigenetically silenced in 15 of 17 these cancers ^[@ref-1]^. Based on the data from the original *in vitro* study ^[@ref-1]^, we predicted epigenetic *MORT* silencing occurs early in human carcinogenesis and therefore could be seen in premalignant lesions, such as ductal carcinoma *in situ* of the breast and colonic adenomas. We used data from clinical samples from published genomic data sets ^[@ref-3]--\ [@ref-8]^ to address this possibility, and indeed, *MORT* loss occurs prior to or at the stage of pre-malignancy and not thereafter ^[@ref-9]^. Taken together these facts suggest that *MORT* transcript has a tumor suppressive role and is not simply an epigenetic "passenger error."

Since our previous analysis of *MORT* in TCGA datasets was not exhaustive and only reported on 17 out of 33 TCGA cancer types, the goal of this short study was to extend our earlier work and complete the analysis of *MORT* DNA methylation associated gene silencing in the final 16 TCGA cancer types.

Methods
=======

We integrated the *MORT* expression level and the DNA methylation state of its promoter region using TCGA data as described before ^[@ref-1]^. The Illumina HiSeq RNA-seq and HumanMethylation450 DNA methylation data for samples of 16 TCGA cancer types listed in [Table 1](#T1){ref-type="table"} were downloaded from the [GDC data portal](https://portal.gdc.cancer.gov/). The data were analyzed in the R programming environment, version 3.4.2 ^[@ref-10]^. The mean RNA-Seq rpkm values for the two exons constituting the *MORT* RNA were plotted against the mean DNA methylation beta value of the 7 CpGs from the *MORT* promoter region for the individual samples of each cancer type. The Spearman correlation coefficient rho between the *MORT* RNA level and the DNA methylation of *MORT* promoter was calculated using the function cor.test.

###### The 16 TCGA cancer types analyzed in this study.

The numbers of primary tumor and normal samples for which both the *MORT* RNA expression and the *MORT* promoter DNA methylation data were available are listed. \*DNA methylation data from HumanMethylation27 platform that covers 2 CpGs out of 7 CpGs covered by HumanMethylation450 were used.

  ---------------------------------------------------------------------------------------------
  TCGA Cancer Type Name                   Abbreviation                      Tumor\    Normal\
                                                                            samples   samples
  --------------------------------------- --------------------------------- --------- ---------
  adrenocortical carcinoma                ACC                               79        0

  cervical squamous cell carcinoma and\   CESC                              304       3
  endocervical adenocarcinoma                                                         

  cholangiocarcinoma                      CHOL                              36        9

  esophageal carcinoma                    ESCA                              184       9

  glioblastoma multiforme                 GBM                               51        1

  kidney chromophobe                      KICH                              66        0

  brain lower grade glioma                LGG                               516       0

  mesothelioma                            MESO                              87        0

  ovarian serous cystadenocarcinoma       OV [\*](#fn1){ref-type="other"}   295       0

  pheochromocytoma and paraganglioma      PCPG                              179       3

  sarcoma                                 SARC                              259       0

  stomach adenocarcinoma                  STAD                              373       0

  testicular germ cell tumors             TGCT                              150       0

  thymoma                                 THYM                              120       2

  uterine carcinosarcoma                  UCS                               57        0

  uveal melanoma                          UVM                               80        0
  ---------------------------------------------------------------------------------------------

Results and discussion
======================

Seven of sixteen analyzed cancer types (CESC, CHOL, ESCA, MESO, SARC, STAD, and UCS) show strong *MORT* silencing by DNA methylation ( [Figure 1](#f1){ref-type="fig"}). The negative correlation rho between *MORT* expression and DNA methylation in these cancers is below -0.5; the DNA methylation level in some tumor samples of these cancers exceeds 0.5 beta (\> 50% DNA methylation), and a large fraction of the tumor samples in these cancer types have very low to no *MORT* expression level ( [Figure 1](#f1){ref-type="fig"}). The correlation of *MORT* expression and promoter DNA methylation in the remaining nine cancer types is also negative; however, the maximum level of the DNA methylation of *MORT* promoter in some of these cancers is either very low (UVM), or a very few tumor samples have *MORT* silenced (ACC, KICH, OV, and THYM), and some of the cancer types (GBM, LGG, PCPG, and TGCT) do not appear to display *MORT* gene silencing ( [Figure 1](#f1){ref-type="fig"}).

![Integration of the *MORT* expression and the *MORT* promoter DNA methylation TCGA data for 16 tumor types.\
The x-axis shows the *MORT* expression level according to RNA-seq and y-axis shows the level of *MORT* promoter DNA methylation according to Illumina HumanMethylation450 microarray. The correlation coefficient rho between the *MORT* expression and the DNA methylation of *MORT* promoter for each tumor type is displayed. The OV has a very low number (10) of samples analyzed by the HumanMethylation450 platform, therefore the data from the HumanMethylation27 platform that covers 2 CpGs out of 7 CpGs covered by HumanMethylation450 were used.](f1000research-7-15158-g0000){#f1}

The analysis presented shows DNA methylation associated *MORT* gene silencing in 7 of 16 TCGA cancer types. Compared to the 17 TCGA cancer types presented in our original study, ^[@ref-1]^ most the 16 cancer types presented here lack their respective normal tissues samples and some of them have lower amounts of tumor samples ( [Table 1](#T1){ref-type="table"}). Nevertheless, the distribution of *MORT* expression and DNA methylation data in tumor samples clearly indicates *MORT* silencing in multiple cancer types ( [Figure 1](#f1){ref-type="fig"}).

Cervical tumors (CESC) have high proportion of *MORT* silencing ( [Figure 1](#f1){ref-type="fig"}); more than 75% of 304 cervical tumor samples have *MORT* promoter DNA hypermethylated and *MORT* silenced. Using TCGA data, a recent study found *MORT* downregulated in cervical cancer ^[@ref-11]^, but surprisingly did not report on or hypothesize potential mechanisms for this transcriptional repression. Here we confirm and extend their initial analysis of *MORT* silencing in cervical cancer and show further that this silencing is strongly linked to aberrant DNA methylation of the *MORT* promoter.

Combined together with the findings from our previous report ^[@ref-1]^, [Table 2](#T2){ref-type="table"} shows *MORT* is silenced by DNA methylation in a super majority of TCGA cancer types (22 of 33). *MORT* loss occurs predominantly due to epigenetic silencing and increased DNA methylation of its promoter in breast cancer ^[@ref-9]^. This could likely be extended to all 22 cancer types with the high fraction of *MORT* negative samples and the high correlation between *MORT* RNA level and *MORT* promoter DNA methylation, where *MORT* likely plays a tumor suppressive role. The other 11 cancer types, with a little to no *MORT* silencing, might have tumor suppressive pathway, where *MORT* is involved, interrupted elsewhere and/or *MORT* may play some additional vital role in tissues these tumors originate from - e.g. prostate, thyroid, brain, testes, or ovary - since these tissues typically have the highest levels of *MORT* RNA ^[@ref-1]^.

###### Summary of *MORT* silencing in all 33 TCGA cancer types.

The cancer types with *MORT* silencing in a large fraction of tumor samples are indicated. Results from this study are indicated (\*), results from our previous report (ref [@ref-1]) are indicated (\*\*).

  -------------------------------------------------------------------------------------------
  Abbreviation   TCGA cancer type name                   *MORT*\
                                                         silencing
  -------------- --------------------------------------- ------------------------------------
  ACC            adrenocortical carcinoma                No [\*](#fn2){ref-type="other"}

  BLCA           bladder urothelial carcinoma            Yes [\*\*](#fn2){ref-type="other"}

  BRCA           breast invasive carcinoma               Yes [\*\*](#fn2){ref-type="other"}

  CESC           cervical squamous cell carcinoma\       Yes [\*](#fn2){ref-type="other"}
                 and endocervical adenocarcinoma         

  CHOL           cholangiocarcinoma                      Yes [\*](#fn2){ref-type="other"}

  COAD           colon adenocarcinoma                    Yes [\*\*](#fn2){ref-type="other"}

  DLBC           lymphoid neoplasm diffuse large\        Yes [\*\*](#fn2){ref-type="other"}
                 b-cell lymphoma                         

  ESCA           esophageal carcinoma                    Yes [\*](#fn2){ref-type="other"}

  GBM            glioblastoma multiforme                 No [\*](#fn2){ref-type="other"}

  HNSC           head and neck squamous cell\            Yes [\*\*](#fn2){ref-type="other"}
                 carcinoma                               

  KICH           kidney chromophobe                      No [\*](#fn2){ref-type="other"}

  KIRC           kidney renal clear cell\                Yes [\*\*](#fn2){ref-type="other"}
                 carcinoma                               

  KIRP           kidney renal papillary cell carcinoma   Yes [\*\*](#fn2){ref-type="other"}

  LAML           acute myeloid leukemia                  Yes [\*\*](#fn2){ref-type="other"}

  LGG            brain lower grade glioma                No [\*](#fn2){ref-type="other"}

  LIHC           liver hepatocellular carcinoma          Yes [\*\*](#fn2){ref-type="other"}

  LUAD           lung adenocarcinoma                     Yes [\*\*](#fn2){ref-type="other"}

  LUSC           lung squamous cell carcinoma            Yes [\*\*](#fn2){ref-type="other"}

  MESO           mesothelioma                            Yes [\*](#fn2){ref-type="other"}

  OV             ovarian serous\                         No [\*](#fn2){ref-type="other"}
                 cystadenocarcinoma                      

  PAAD           pancreatic adenocarcinoma               Yes [\*\*](#fn2){ref-type="other"}

  PCPG           pheochromocytoma and\                   No [\*](#fn2){ref-type="other"}
                 paraganglioma                           

  PRAD           prostate adenocarcinoma                 No [\*\*](#fn2){ref-type="other"}

  READ           rectum adenocarcinoma                   Yes [\*\*](#fn2){ref-type="other"}

  SARC           sarcoma                                 Yes [\*](#fn2){ref-type="other"}

  SKCM           skin cutaneous melanoma                 Yes [\*\*](#fn2){ref-type="other"}

  STAD           stomach adenocarcinoma                  Yes [\*](#fn2){ref-type="other"}

  TGCT           testicular germ cell tumors             No [\*](#fn2){ref-type="other"}

  THCA           thyroid carcinoma                       No [\*\*](#fn2){ref-type="other"}

  THYM           thymoma                                 No [\*](#fn2){ref-type="other"}

  UCEC           uterine corpus endometrial\             Yes [\*\*](#fn2){ref-type="other"}
                 carcinoma                               

  UCS            uterine carcinosarcoma                  Yes [\*](#fn2){ref-type="other"}

  UVM            uveal melanoma                          No [\*](#fn2){ref-type="other"}
  -------------------------------------------------------------------------------------------

In summary, our findings show that the *MORT* gene is one of the most common epigenetic aberrations seen in human cancer. Coupled together with *MORT* silencing occurring early in the temporal arc of human carcinogenesis it strongly supports a tumor suppressive role for *MORT*.

Data availability
=================

Illumina HiSeq RNA-seq and HumanMethylation450 DNA methylation data for TCGA cancer types used in the present study can be downloaded from the [GDC data portal](https://portal.gdc.cancer.gov/).

The results shown here are based upon data generated by the TCGA Research Network: <http://cancergenome.nih.gov/>.
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This brief article provides an analysis of MORT epigenetic silencing across 16 TCGA tumour types not previously reported by the authors enabling assessment across all TCGA tumour types. MORT silencing seems to  be a key early event in carcinogenesis. This indicates that further studies of MORT biology are required as well as investigation of MORT methylation as a potential biomarker.
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STRENGTHS: The authors utilize the TCGA database to extend their previous studies on MORT that has been primarily characterized in breast cancer, but also observed to undergo silencing in 15 out of the 17 most common cancers. The current work takes this analysis deeper into the 33 TCGA cancer types and perform a more thorough analysis of the DNA methylation associated with the 16 cancer types evaluated here.

SUGGESTIONS FOR IMPROVEMENT:

 -The authors make a bold statement that "the MORT gene is one of the most common epigenetic aberrations seen in human cancer". This statement is not supported by the data presented. In order to make a statement of this level, the authors would have to provide comparisons to other documented genes that undergo a high frequency of epigenetic alteration. 

-This statement becomes more difficult to make when considering that several of the tumors present do not have normal counterparts for comparison. We therefore do not know if those tissue types whether the DNA methylation is abnormal or typical for the tissue type. 

-Authors should consider revising some of the scales on the graphs in Figure 1 to highlight the lack of methylation (for example, in testicular germ cell tumors). Similarly, the cutoff for methylation could be shown by a dotted line or similar feature. 

-The location of methylation relative to the MORT gene would be informative. Of the tumor types that are methylated, are the same regions methylated across types? 

-The authors should be cautious not to overstate their conclusions throughout the text since the conclusions are speculative without experiments to support their statements. Nevertheless, these correlations present interesting speculation and avenues for further investigations.
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The authors present a straightforward study of DNA methylation and RNA expression of the lncRNA MORT in 16 TCGA cancer types not previously reported.  Most of the paper is clearly presented and the conclusions are reasonable.  Suggestions for improvement are presented below.

1\) Statements are made regarding MORT being "one of the most common" epigenetic aberrations seen in human cancer.  No support for this statement is presented.

2\) The classification of some tumor types as showing "strong" MORT silencing by DNA methylation, and other tumor types as not showing this, is arbitrary.  A quantitative definition is needed.

3\) Fig 1 might be clearer if presented in two panels, subdivided by whether the quantitative definition of "strong silencing" is met.  The same is true for Table 2, which could be subdivided into two parts.

4\) Since normal samples were not available for many of the tumors profiled, a more accurate statement might be "DNA methylation regulation" rather than "DNA methylation silencing," as reduced expression in tumors as compared to normal tissues was not shown.

5\) A diagram showing the MORT gene and the position of the methylation sites examined by the TCGA would be helpful.

6\) Can the authors reference any data, e.g. from other publications, showing that DNA methylation actively suppresses MORT expression, by for example turning on MORT expression using treatment with a DNA methyltransferase inhibitor?

7\) In the introduction, the statement "prior to or at the stage of pre-malignancy and not thereafter" is confusing, and gives the impression that MORT becomes hypomethylated, or its expression is elevated, in tumors as compared to pre-malignant lesions.  A better way to phrase this would be to say e.g. that "MORT is repressed in pre-malignant lesions and remains repressed in tumors."

8\) The final sentence in the discussion uses the wording "strongly supports" when "suggests" would be more accurate, given the absence of functional data showing tumor suppression by MORT.
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